[
  {
    "ts": "2025-12-23T03:11:42+00:00",
    "headline": "The Bull Case For Incyte (INCY) Could Change Following New Minjuvi And Zynyz Approvals In Europe And Japan",
    "summary": "In recent days, Incyte announced that the European Commission and Japan’s Ministry of Health, Labour and Welfare approved Minjuvi (tafasitamab) and Zynyz (retifanlimab) in new combination regimens for relapsed or refractory follicular lymphoma and advanced squamous cell carcinoma of the anal canal, expanding treatment options across major oncology markets. These approvals meaningfully broaden Incyte’s oncology footprint in Europe and Japan while deepening its presence in chemotherapy-free...",
    "url": "https://finance.yahoo.com/news/bull-case-incyte-incy-could-031142298.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "c2be2f28-23fd-37f6-80d2-bc2f17d0e78f",
      "content": {
        "id": "c2be2f28-23fd-37f6-80d2-bc2f17d0e78f",
        "contentType": "STORY",
        "title": "The Bull Case For Incyte (INCY) Could Change Following New Minjuvi And Zynyz Approvals In Europe And Japan",
        "description": "",
        "summary": "In recent days, Incyte announced that the European Commission and Japan’s Ministry of Health, Labour and Welfare approved Minjuvi (tafasitamab) and Zynyz (retifanlimab) in new combination regimens for relapsed or refractory follicular lymphoma and advanced squamous cell carcinoma of the anal canal, expanding treatment options across major oncology markets. These approvals meaningfully broaden Incyte’s oncology footprint in Europe and Japan while deepening its presence in chemotherapy-free...",
        "pubDate": "2025-12-23T03:11:42Z",
        "displayTime": "2025-12-23T03:11:42Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FqD7IP1YjoMtOLiC1foWBQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DnvRJ7zmyZqa8oFdfcLgCg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bull-case-incyte-incy-could-031142298.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bull-case-incyte-incy-could-031142298.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T14:07:40+00:00",
    "headline": "Is It Too Late To Consider Incyte After A 45% Rally In 2025?",
    "summary": "If you are wondering whether Incyte at around $100 a share is still good value or if the easy gains are behind it, you are not alone. This is exactly the question we are going to unpack. The stock is up 44.8% year to date and 44.2% over the last year, even after a modest 1.3% pullback over the past month following a 2.1% rise in the most recent week. This suggests that the market is rapidly rethinking its growth and risk profile. That shift has been driven by a stream of positive pipeline...",
    "url": "https://finance.yahoo.com/news/too-consider-incyte-45-rally-140740292.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "530f30e6-4f1c-3f7a-af10-b339834e183f",
      "content": {
        "id": "530f30e6-4f1c-3f7a-af10-b339834e183f",
        "contentType": "STORY",
        "title": "Is It Too Late To Consider Incyte After A 45% Rally In 2025?",
        "description": "",
        "summary": "If you are wondering whether Incyte at around $100 a share is still good value or if the easy gains are behind it, you are not alone. This is exactly the question we are going to unpack. The stock is up 44.8% year to date and 44.2% over the last year, even after a modest 1.3% pullback over the past month following a 2.1% rise in the most recent week. This suggests that the market is rapidly rethinking its growth and risk profile. That shift has been driven by a stream of positive pipeline...",
        "pubDate": "2025-12-23T14:07:40Z",
        "displayTime": "2025-12-23T14:07:40Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FqD7IP1YjoMtOLiC1foWBQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DnvRJ7zmyZqa8oFdfcLgCg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/too-consider-incyte-45-rally-140740292.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/too-consider-incyte-45-rally-140740292.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]